Natural products (NP) have historically been a rich source of lead molecules in drug discovery based on their capability to create unique and diverse chemical structures.
Introduction
In recent years the development of novel drugs has become increasingly difficult, expensive and time consuming. It is estimated that more than 800 million USD and an average of 14.2 years are needed for a novel drug application (NDA) approval.
Both factors are rapidly increasing with time while the output of newly launched drugs has dropped (332, 333) . The introduction of high throughput screening (HTS), a process which allows the testing of a large number of samples on certain molecular targets, was expected to shorten the discovery route. To fully use its high potential, HTS requires a large number of compounds to screen, in the order of thousands of samples per day (334). In order to meet this demand, high throughput synthesis and combinatorial chemistry were developed. Concomitantly, further development in the field of structural biology and genomics, e.g. cloning and expression technology resulting in the production of various purified human receptors and enzymes which could be studied at a molecular level, produced a sharp increase in the number of possible molecular targets, demanding more drug-based libraries of a wide chemical diversity to screen (335) . The combination of these new strategies seemed very powerful and the delivery of a large number of novel leads was expected (336). However, these expectations were shown to be greatly overrated as the number of new active compounds that made it to the market in the past two decades reached its lowest level ever in 2002 with an insignificant improvement in 2003 (1, 336, 337) . Sorafenib, a multikinase inhibitor indicated for advanced renal cancer, is the single synthetic drug derived from combinatorial chemistry approved by Food and Drug Administration for clinical use (1). The fact, this increased HTS screening capacity and number of novel molecular targets has failed to produce an increase of new lead compounds poses the question on whether this is due to limitations in the innovative aspects of the discovery process itself, e.g. generation of compounds limited chemical diversity, or because of the potential of natural products (NP) has been de-emphasized in the past few years (332).
The possibility of combining NP extract libraries with HTS also seems interesting, though not always an easy task. Several reasons for the incompatibility of NP and HTS have been described (332, 336) . The complexity of NP extract which is a complex mixture of mostly uncharacterized compounds which may mask the bioactivity of target compounds or cause false positive results is the most common hurdle. The large dynamic range (e.g. the difference in the levels of major compounds as compared to that of minor compounds, differences in polarity, in boiling or evaporating points, etc) which may affect compounds solubility makes the integration of NP and HTS more complicated. The differences between areas where plants are grown, the methods of production and processing of plants are also important since these might affect the chemical profile of the NP (338, 339). The intellectual property issue in natural product outsourcing is another problem. Thus, the drug discovery process using plant sources was almost abandoned (333, 340) . Companies such as Glaxo Wellcome, Smith Kline & French, and Pfizer, gradually eliminated their NP screening programmes while others such as Merck and Novartis continued their exploration but focussed on microbial sources (336).
The failure to increase the number of new drugs delivered to the market has placed the drugs discovery programs of pharmaceutical companies under scrutiny.
Looking back to the past two decades, of the 877 novel medicines developed between 1981 and 2002, 6% were NP, 27% were NP derivatives and 16% were synthetic products developed on the basis of a NP model (337), indicating that NP is still an important source of novel leads for therapeutical drugs. This situation has led to a renewed interest in NP in the drug discovery programs. Therefore, it is a challenging task to make NP available for the drug discovery arena.
Most NP drug discovery work follows "the silver bullet" approach as is usual in present Western medicine, in which the search is focused on single compounds with a particular biological activity (single target-single compound paradigm) tested at molecular level (e.g. receptor binding inhibition or enzyme screening) (341). This approach which has been responsible for the successful delivery of many potent drugs in the past, such as the statins to lower cholesterol level and huperzine A for Alzheimer"s disease (342), is not actually the best approach for NP studies since the presence of synergism and pro-drugs in an extract can be misleading (341). It is also one of the reasons for the long time line and high costs which the pharmaceutical companies have to deal with when working with NP. Shifting the silver bullet paradigm to a more holistic approach, which is actually the philosophy of some traditional medicine such as Traditional Chinese Medicine (TCM) and Ayurveda, is now evolving into a new trend Chapter 4 104 (338, 341, 343) . In a holistic approach, a whole herbal preparation, which consists of numerous multi components, is viewed as one active entity with effects on multiple targets in living organisms (342, 343) . For such an approach, the response of the whole system needs to be observed with all possible tools such as clinical trials or experimental animal models, where both classic physiological observations (e.g. blood pressure, analgesic activity, sedative) and modern molecular observation (gene expression, proteome, metabolome) can be used to obtain better insight into different changes in organism. This is known as a systems biology approach (341).
Among these "omics" methods, metabolomics, a relatively new member, is thought to be the most informative as regards understanding systems biology since it reflects the genotype (344). Therefore it is a valuable tool to use in the provision of the information required in this new approach which is particularly interesting for the study of medicinal plants. It thus offers new opportunities for NP in the drug discovery arena.
This review will discuss the chemical diversity of compounds present in NP as compared to synthetic compounds, the obstacles which might limit NP integration with the new emerging drug discovery technologies, the shift in tendency from a reductionist to a holistic approach in NP research and how metabolomics can help to narrow the gap between NP and the demand of modern drug discovery, and helping to turn NP and medicinal plants into a unique drug source.
Natural products as a drug source; their advantages and limitations
Factors which distinguish NP from synthetic chemicals include their incomparable molecular diversity and biological functionality (345). Starting with only a few building blocks of NP provided by the biosynthesic pathways, the action of various "decorating" enzymes provide a large diversity of end products with different functionalities (345-347). Compared to products resulting from combinatorial chemistry libraries which usually lack chirality and structure rigidity, two important requirements for pharmaceutical drug-like properties (345), NP have privileged structures which are able to interact with proteins and other biological targets for specific purposes (335).
To address the question of how the unique structural properties of NP are able to complement the chemical space of synthetic compounds, the comparison of the major structural differences between combinatorial compounds, drugs, and NP molecules has been made. It is obvious that current commercial drugs and NP share more similarities in several topological pharmacophore patterns. The important differences between NP and synthetic compounds include the number of chiral centers, the prevalence of aromatic rings, the presence of complex ring systems, and the degree of the saturation of the molecule as well as the number and ratios of different heteroatoms (348). Natural products have a higher number of chiral centers, a higher number of oxygen atoms instead of nitrogen, sulfur and halogen containing groups present than in synthetic compounds. Natural products have a lower ratio of aromatic ring atoms to total heavy atoms, and a higher number of solvated hydrogen bond donors and acceptor functional groups. These characteristics are favorable attributes for a drug candidate profile (1, 337, 348, 349) . With these unique properties, in general, NP actually has more drug-like properties than synthetic compounds (348, 350).
However, a NP-based drug discovery project also poses some challenges, mostly connected with their presence within a complex matrix with all kind of active compounds (335, 336, 340, 347, (350) (351) (352) :
-The first challenge is dereplication which is the rapid identification of known and unknown compounds from partially purified mixtures. In a number of test systems, common plant products which have been found to be active e.g. unsaturated fatty acids on adenosine and GABA receptors or tannins on enzymes based bioassays, have to be identified at the very beginning of the study of an active extract.
-Interaction between metabolites present in extracts. Extracts consist of mixtures of many compounds requiring an elaborate purification to isolate new pure compounds.
Another problem of complex extracts is the presence of antagonism or synergisms which might occur between components in a mixture, posing a major intellectual challenge which can be painstakingly time consuming.
-Structure determination by spectroscopic methods.
-Large scale production of the active component is sometimes an obstacle as the identified NP lead might be a minor compound of the extract, or the supply of the material for extraction might be limited.
-Sourcing of authenticated plants, a very important issue for quality control. For example, some plants have congener substitutes which have an active principal content which may be different to the original one.
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Last but not least, biodiversity and intellectual property issues can be another complicating factor related to this context.
Previous efforts to increase the number of compounds for drug candidates
Because of the demand to speed up the drug discovery timeline and to reduce costs, the in-vitro screening system has become the preferred method. The use of animal tests or isolated organs was abandoned for more specific testing targets at a molecular level (reductionist mode) (353). Following this trend, there are two crucial prerequisites to start the drug discovery process: a large high quality library of candidates to be screened, and a reliable and sensitive assay to screen the activity. Combinatorial chemistry was developed to address the first need (354 Therefore it is necessary not to focus only on quantity but also consider quality of both library and assays. One suggestion made on this matter, was to introduce simple ADMET parameters at the early stage of screening and the more sophisticated ones at a later stage (188). The appropriate application of virtual screening as a complement to a screening campaign to enrich the hit rate and reduce the number of false positive has been suggested as well (358, (361) (362) (363) . Most virtual screening is guided by the structure The aforementioned efforts, however, did not successfully fulfill the high expectation of increasing productivity. The tremendous amount of money spent was not counterbalanced with the number of new approved drugs (361). However, all these methods will result in all companies having the same basic information on targets and probably ending up with the same compound, reducing the chance for real innovation with this approach will be limited. This has encouraged reconsidering NP as a drug source.
Efforts to combine natural products with new technologies
Many studies reported possible approaches which could potentially help to overcome the above mentioned problems in the NP drug discovery process. Solutions to address the incompatibility of NP extracts with HTS technology were proposed,
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Constructing a high quality natural product library
Several strategies to construct better NP libraries and to improve methods to screen these libraries have been reviewed. The advantages and limitations of a crude extract library, pre-fractionated library, or pure compound library have been described (350). Crude extract libraries are simple to make, the obstacles appearing in the identification and dereplication steps. A pre-fractionated library can be effective to overcome these hurdles since the less complex fractions require fewer purification steps and the interference of unwanted compounds is reduced, while more investment is required both for fraction preparation and for the HTS assay since several samples are obtained from a single extract. The pure compound library is preferred since it is able to move forward directly after finding a hit.
The strategy employed to build a fraction library as a compound source for HTS from Chinese herbal formulations reported to treat atherosclerosis has been described. Medium pressure liquid chromatography with a gradient solvent system followed by reverse phase semi-preparative HPLC was used as a filtering method to remove unfavorable compounds lacking desirable ADME properties and to prepare semi-crude extracts with different polarity. The fractions were characterized and identified by LC-DAD-ESI-MS. A component detection algorithm (CODA) was used to reduce noise and background of the chromatograms which then were presented as a histogram describing compound molecular distribution. Small molecules (less than 500 Da) were characterized by retention time, molecular weight, UV absorbance, and crude drug origin. In this way, 36 major compounds of each fraction were identified and after cell based multiples bioassay screening, validation and dereplication steps, 7 hits were found (364).
Improving fractionation methods
Another study focused on sample fractionation using an automatic multiple solid phase extraction (SPE) method (351). Several different solid phases were used thus reducing the complexity of an extract from a microbial fermentation broth, leading to a more reliable and reproducible screening result.
Improving dereplication and identification steps
A fast dereplication and identification of novel active compounds can be achieved by direct coupling of the bioassay to liquid chromatography (362, 365 ). An example is the post-column acetylcholine esterase (AChE) inhibitor assay. After centrifugal partition chromatography (CPC) pre-fractionation and bioactivity testing, the most active Narcissus "Sir Winston Churchill" fraction was injected into an online biochemical detection system coupling HPLC-UV-MS for AChE inhibitor activity. This system enabled a fast dereplication, allowing the identification of known compounds. It Practical examples of the application of various hyphenated LC-NMR techniques for rapid screening, dereplication, and structure determination of active compounds from natural extract has been published (374).
Virtual screening
The application of virtual screening of known NP has been proposed (375). NP are still an incredible rich source of new drugs and because of the better understanding of protein-ligand interaction properties, NP virtual screening can constitute an alternative way to accelerate the drug discovery process. Many advantages have been described including higher capacity, reduction in the number of experiments for testing and isolating compounds, the ability to calculate the possible interaction of compounds and targets, and the possibility of applying additional filters such as ADME and druglike properties to improve the hit quality. Strategies to combine virtual screening and classical methods in NP exploration were proposed; (1) Direct screening of a 3D database of NP using available target information and pharmacophore model of specific activity, followed by the isolation of hits once the results are confirmed by experimental data. (2) Extracts were roughly screened experimentally to select the active ones, or the specific activity was explored through an ethnopharmacological approach, the result of which was then virtually screened using a pharmacophore model of the target, followed by isolation.
Metabolomics
Metabolomics is one of the new "omics" fields, joining genomics, Although MS sensitivity is probably the best among analytical methods, there are some limitations for its application in metabolomics. For example, the different sensitivity of the detection of molecules and its reproducibility are important issues.
Because of different detector response, calibration curves are needed for each individual compound for absolute quantification, this being totally unrealistic considering the hundreds of signals that appear in a metabolomic profile. In this case, NMR spectrometry is the method of choice, in absence of which only a relative quantification of the individual compounds in different experiments can be made (386).
The application of NMR for metabolic profiling of plant tissue extracts has been reviewed by several authors (12, 13, 392) . Reproducibility is the most important criteria for developing a metabolomics technology platform, and NMR is the most suited choice even though its sensitivity is not as high as MS (1 μM -1 mM in NMR tube) (12, 13). The simple and fast sample preparation, short measurement time, the availability of less automatization and advanced data analysis methods, plus the possibility to elucidate structures of known or unknown compounds in a complex mixture using advanced two-dimensional (2D) NMR methods, are further advantages (12, 13). 
Data processing
Various applications of metabolomics in bioactivity screening of natural product
Metabolomics to improve identification and dereplication steps
The reductionist approach as described above is still widely applied in many NP drug discovery projects, i.e. in bioassay guided isolation work. In this approach, the rapid dereplication of known actives and identification of novel actives is essential.
Addressing this issue, some papers have described the way in which a metabolomics approach consisting in the use of various analytical methods followed by appropriate MVDA can be used to shorten the reductionist bioassay driven isolation route, especially in the identification and dereplication step.
In one study, the hierarchical cluster (HCA) analysis of the chromatographic profiles of 500 lipidic extracts of bacteria, resulted in the identification of 2 new oligoprenylsesquiterpenes and 2 new N-(2-arylethyl) amides, though the bioactivity profile was not reported here. The HCA was chosen instead of PCA since the number of principal components representing more than 50% of the variance was much too high for PCA. Principal component analysis is more suitable for a large data set of similar compounds, which was not the case in this project. The use of this clustering method was able to advance the dereplication step and to avoid redundant analyses for selection of strains containing new NP (395). However, only one metabolite unique to M. xanthus was known, that is DKxanthanes.
Intraspecific diversity in the metabolite profiles of 98 Myxococcus xanthus strains originated from 78 locations worldwide was rapidly explored by means of fast chromatographic separation (UPLC)-coupled ESI-TOF-MS and PCA. As a result, 37
candidates for novel compounds were identified but their bioactivities were not reported (399).
Metabolomics for quality control of phytomedicines
At present, the most popular application of metabolomics in NP research is for Metabolomics can also be used to detect adulterations of herbal preparations with similar species but with low levels of the desired active compound(s). The 1 H NMR and PCA was used to verify that the anti-malaria capsules produced by one specific company did not contain Artemisia annua as labeled but Artemisia afra, which has never been reported to contain the active compound artemisinin or any of its derivatives (406). Instead of 1 H NMR, the use of HPLC fingerprints followed by application of PCA and PLS-DA was applied to examine the authenticity of the traditional Chinese medicines Pericarpium Citri Reticulatae and Pericarpium Citri
Reticulatae Viride which contain Citrus reticulate "Chachi", Citrus reticulata "Dahongpao" and Citrus erythrosa Tanaka as well that of commercial preparations containing a mixture of many tangerine peels which had been made with new tangerine mutations of uncertain quality (407).
Metabolomics to link chemical profile and bioactivity pattern of phytomedicines
As previously described, a reductionist approach focusing on a single active compound is necessary in some cases, but in case of St. John"s Wort extract, where no single compound or even group of compounds have been found to be responsible for its activity, the possibility of synergism and pro-drugs is evident, and a holistic in-vivo approach would be more valuable to guarantee its therapeutic efficacy (341, 343).
Animal experiments and clinical trials are two classical ways to conduct in-vivo
experiments, but the time required and costs involved make this option practically non viable. Furthermore, if these tests are performed with extracts of uncertain composition, results will invariably be unreliable or inconsistent. Recently new approaches are evolving which might help to get a better view of the mode of action of herbal or natural products and lead to the possibility of obtaining proof and guarantee of their pharmacological activity over different batches. These approaches are based on considering the NP holistically, i.e. on the bulk of chemical constituents rather than focusing on certain individual components or groups of compounds. On the other hand, the changes caused by a sample on the transcriptome, proteome and/or metabolome patterns can be compared with those observed after treatment with known drugs rather than looking only at certain specific changes. Genomics, proteomics, and metabolomics platforms will be crucial since they allow the identification of detectable protein/genes or compounds which might relate to the biological activity of complex extract (343).
This may shift the paradigm in the development and application of complex plant/phytocompound mixtures in modern medicine (408). Moreover, by measuring the effect of a complex extract administered to a living organism, either in-vitro or in-vivo, it is possible to identify the compound or combination of compounds correlated with activity. Besides, new or unsuspected mode(s) of action and targets might also be revealed in this approach (341).
Several papers discussed a metabonomics approach to study various aspects of natural products extracts such as bioavailability, toxicity, and proof of efficacy. officinale, and the observed total anti-inflammatory activity. Therefore, it was concluded that other compounds, unidentified to date which contributed to this activity had to be detected and quantified in order to guarantee the bioactivity of a particular
Zingiber sample (410). 
Proof of efficacy and mode of action of herbal medicines
The in-vitro cellular effects of Cannabis from different cultivars and preparations were analyzed using a proteomic and transcriptomic platform (338). In another case, the in-vivo effect of Ginkgo on rats was studied by applying a 1 H-NMR and supervised MVDA method to measure metabolites in their urine (338). The effect of three traditional Chinese medicines on insulin resistance APOE*3-Leiden transgenic mice which are highly responsive in their plasmatic lipids to dietary treatments was also studied. The LC-MS measurement combined with MVDA was applied to three TCM preparations to discover which was most effective TCM but had the lowest toxicity 120 trimethylamine-N-oxide. It showed that after TFE intervention, the 24-month-old rats urine profile was shifted towards that of 18-months-old rats (413). In another case, the study of Epimedium brevicornum Maxim, was undertaken. This herbal medicine, one of the most popular in China is used for toning the kidney and strengthening bones, but the kind of constituents responsible for its pharmacological effect, and the mechanism through which it affects the entire body metabolism was unknown. The plasma metabolites of rats from three different treatments (pre-hydrocortisone intervention, post-hydrocortisone intervention, and Epimedium brevicornum Maxim. treated) were analyzed using UPLC-MS followed by PCA. The distinct increase of the level of three metabolites was found after hydrocortisone intervention, one of them identified as ethylindole-3-crylic acetate. The result showed that after Epimedium brevicornum
Maxim treatment, the plasma metabolite profile was restored closer to that of the prehydrocortisone intervention. Of the four compounds of this herbal preparation detected in plasma (epimedin C, icariin, icariside II, and 2″-O-rhamnosoyl icaride), epimedin C and icariin were also found in urine, and it was concluded that those might be the active ones (414).
The efficacy and the mechanism of action of the traditional Chinese medicine preparation known as Xindi soft capsules (consisting of sea buckthorn flavonoids and sea buckthorn berry oil) used to treat blood stasis, was studied by UPLC combined with quadrupole time-of-flight tandem mass spectrometry (UPLC-QTOF-MS) followed by PCA and PLS-DA analysis. Blood stasis includes hematological disorders such as haemorrhage, nasal congestion, thrombosis, and local ischemia (microclots).
The comparison of the urinary metabolite pattern obtained for 5 groups of rats (healthy control group, acute blood stasis model group, low dose group of Xindi soft capsule, middle dose group of Xindi soft capsule, high dose group of Xindi soft capsule),
showed that the treated groups were located between the acute blood stasis model group and the healthy control group. Confirmation by hemorheological analysis proved that within the treated group, especially in the case of the highest dose group, the urine metabolite pattern tends toward that of the control group. Some potential biomarkers were identified as well, such as cholic acid, phenylalanine and kynurenic acid (415).
Bioavailability and fate of natural compounds assessment
The metabonomics approach was successfully applied to study the 
Safety and toxicity of herbal medicines assessment
There are also many reports on the application of the metabonomics approach to solve the two other major issues related to the quality control of herbal medicinessafety and toxicity. The mechanism of the toxicity of aristolochic acid was studied by analyzing the urine of rats submitted to intra-peritoneal injection of aristolochic acid and several toxins with known modes of action. The PCA, confirmed by biochemical parameter analysis, allowed researchers to conclude that aristolochic acid induced the damage of renal proximal tubules and medulla, accompanied with a slight hepatic lesion (417). Similarly, the toxicity of Hei-Shun-Pian (the processed lateral root of Aconitum carmichaelii Debx., Ranunculaceae) was evaluated using the 1 H NMR spectral metabolic profile of urine and plasma samples of rats after 5 days oral treatment with the decoction of Hei-Shun-Pian at different doses. Hei-Shun-Pian is a traditional
Chinese medicine with analgesic, anti-pyretic, anti-rheumatoid arthritis and antiinflammatory effects. The C-19 diterpenoid alkaloid aconitine and a series of its derivatives are suggested to be the active principles, but some of those are also very toxic and have narrow therapeutic windows (LD50/ED50). Studying the PCA and PLS analysis of 1 H NMR data, it was found that the primary differences between the plasma 
Conclusions and perspectives
In response to the renewed interest in NP, several strategies have been designed to improve NP lead finding. Strategies aimed at improving the compatibility of natural products with high throughput screening requirements by improving the NP libraries shorten the discovery route, using advanced analytical methods and combining them with online bioassays, and selecting new approaches which can rapidly provide evidence of efficacy.
The reductionist approach is still widely used in NP drug discovery studies. It is evident that metabolomics has shown to be a potent facilitator in the recovery of NP as excellent sources for novel leads, and even further, as a means to discover novel targets, as the strength of the "omics" based approaches lies greatly in the fact that results can be stored for long term data mining.
